U.S. markets closed
  • S&P Futures

    4,521.75
    -6.25 (-0.14%)
     
  • Dow Futures

    35,437.00
    -40.00 (-0.11%)
     
  • Nasdaq Futures

    15,336.00
    -41.50 (-0.27%)
     
  • Russell 2000 Futures

    2,286.60
    -0.90 (-0.04%)
     
  • Crude Oil

    84.25
    +0.38 (+0.45%)
     
  • Gold

    1,783.10
    -1.80 (-0.10%)
     
  • Silver

    24.40
    -0.05 (-0.18%)
     
  • EUR/USD

    1.1663
    +0.0011 (+0.09%)
     
  • 10-Yr Bond

    1.6360
    +0.0010 (+0.06%)
     
  • Vix

    15.49
    -0.21 (-1.34%)
     
  • GBP/USD

    1.3822
    -0.0004 (-0.03%)
     
  • USD/JPY

    114.3500
    +0.0210 (+0.02%)
     
  • BTC-USD

    65,487.00
    +1,291.83 (+2.01%)
     
  • CMC Crypto 200

    1,548.64
    +67.84 (+4.58%)
     
  • FTSE 100

    7,223.10
    +5.57 (+0.08%)
     
  • Nikkei 225

    29,168.56
    -86.99 (-0.30%)
     

AKCEA THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of AKCA and Encourages Investors to Contact the Firm

·2 min read

NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Akcea Therapeutics, Inc. (NASDAQ: AKCA) breached their fiduciary duties or violated the federal securities laws in connection with the company’s merger with Ionis Pharmaceuticals, Inc. (NASDAQ: IONS).

Click here to learn more and participate in the action.

On August 31, 2020, Akcea announced that it had signed an agreement to be acquired by Ionis for approximately $500 million. Pursuant to the merger agreement, Akcea stockholders will receive $18.15 in cash for each share of Akcea common stock owned. The deal is scheduled to close in the fourth quarter of 2020.

Bragar Eagel & Squire is concerned that Akcea’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Indeed, Akcea stock has recently traded above the $18.15 merger consideration. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Akcea’s stockholders.

If you own shares of Akcea and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato or Alexandra Raymond by email at investigations@bespc.com or telephone at (646) 860-9157, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:
Bragar Eagel & Squire, P.C.
Melissa Fortunato, Esq.
Alexandra Raymond, Esq.
investigations@bespc.com
www.bespc.com